Miniatura

Fitxers

853903.pdf (655.27 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2024-02-01

Llicència de publicació

cc-by (c) Pelgrim, T.A.D. et al., 2024
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/220332

A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/ph17020151

Resum

Background: Pharmacological treatment for psychiatric disorders has shown to only be effective in about one-third of patients, as it is associated with frequent treatment failure, often because of side effects, and a long process of trial-and-error pharmacotherapy until an effective and tolerable treatment is found. This notion emphasizes the urgency for a personalized medicine approach in psychiatry. Methods: This prospective patient- and rater-blinded, randomized, controlled study will investigate the effect of dose-adjustment of antidepressants escitalopram and sertraline or antipsychotics risperidone and aripiprazole according to the latest state-of-the-art international dosing recommendations for CYP2C19 and CYP2D6 metabolizer status in patients with mood, anxiety, and psychotic disorders. A total sample of N = 2500 will be recruited at nine sites in seven countries (expected drop-out rate of 30%). Patients will be randomized to a pharmacogenetic group or a dosing-as-usual group and treated over a 24-week period with four study visits. The primary outcome is personal recovery using the Recovery Assessment Scale as assessed by the patient (RAS-DS), with secondary outcomes including clinical effects (response or symptomatic remission), side effects, general well-being, digital phenotyping, and psychosocial functioning. Conclusions: This is, to our knowledge, the first international, multi-center, non-industry-sponsored randomized controlled trial (RCT) that may provide insights into the effectiveness and utility of implementing pharmacogenetic-guided treatment of psychiatric disorders, and as such, results will be incorporated in already available dosing guidelines.

Matèries

Trastorn bipolar, Depressió psíquica, Ansietat, Medicina personalitzada, Esquizofrènia, Psicosi, Salut mental

Matèries (anglès)

Manic-depressive illness, Mental depression, Anxiety, Personalized medicine, Schizophrenia, Psychoses, Mental health

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Institut de Neurociències (UBNeuro))

Citació

PELGRIM, Teuntje a. d, PHILIPSEN, Alexandra, YOUNG, Allan h., JURUENA, Mario, JIMÉNEZ MARTÍNEZ, Esther, VIETA I PASCUAL, Eduard, JUKIĆ, Marin, VAN DER EYCKEN, Erik, HEILBRONNER, Urs, MOLDOVAN, Ramona, KAS, Martien j.h., JAGESAR, Raj r., NÖTHEN, Markus m., HOFFMANN, Per, SHOMRON, Noam, KILARSKI, Laura l., VAN AMELSVOORT, Therese, CAMPFORTS, Bea, VAN WESTRHENEN, Roos. A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study. _Pharmaceuticals_. 2024. Vol. 17, núm. 2. [consulta: 12 de abril de 2026]. ISSN: 1424-8247. [Disponible a: https://hdl.handle.net/2445/220332]

Exportar metadades

JSON - METS

Compartir registre